TASC D型主髂动脉闭塞症腔内治疗的近期效果观察  

The short-term effect of endovascular treatment of TASC-D aortoiliac occlusion disease

作　　者：张宏光[1] 韩冰[1] 周辰光[1] 吉国辉[1] 杨铮[1] 张亮[1] 赵磊[1] 范忠臣[1] ZHANG Hong-guang, HAN Bing, ZHOU Chen-guang, JI Guo-hui, YANG Zheng, ZHANG Liang, ZHAO Lei, FAN Zhong-cheng.(Department of Vascular Surgery, The No.2 Hospital of Baoding, Baoding 071051, Chin)

机构地区：[1]保定市第二医院血管外科,河北保定071051

出　　处：《中国血管外科杂志（电子版）》2018年第1期32-34,37,共4页Chinese Journal of Vascular Surgery(Electronic Version)

摘　　要：目的观察TASC D型主髂动脉闭塞症腔内治疗的近期效果。方法回顾性分析2015年1月至2016年12月在本院腔内治疗的36例(46条患肢)TASC D型主髂动脉闭塞症患者的临床治疗资料,观察腔内治疗成功率、手术前后踝肱指数(ABI)变化、术后并发症,并于术后6、12个月进行随访统计通畅率变化。结果 43条患肢手术成功,手术成功率93.48%(43/46);腔内治疗成功患者ABI从术前的0.42±0.16提高到术后的0.83±0.21(P<0.01);术后随访6、12个月的通畅率分别为97.67%、90.70%。术中髂动脉破裂1例(3.03%),术后血肿形成1例(3.03%),未出现动静脉瘘、深静脉血栓、假性动脉瘤等并发症。结论腔内治疗TASC D型主髂动脉闭塞症创伤小,通畅率高且并发症少,近期效果显著,是一种安全有效的治疗方法。Objective To observe the short-term effect of endovascular treatment of TASC-D aortoiliac occlusion disease. Methods The clinical data of 36 cases（46 limbs） of type TASC-D aortoiliac occlusion disease with endovascular treatment in our hospital from January 2015 to December 2016 were analyzed retrospectively. The success rate of endovascular treatment before and after surgery, ankle brachial index（ABI） changes, postoperative complications, and patency rate changes at the follow-up of 6 and 12 months were observed. Results 43 limbs were successful, the success rate of the operation was 93.48%（43/46）. ABI of successful limbs improved from（0.42 ±0.16） preoperatively to（0.83 ±0.21） postoperatively（P〈0.01）. The patency rate of 6 and 12 months was 97.67% and 90.70%. One case（3.03%） suffered hematoma,while one case（ 3. 03 %） suffered iliac artery rupture after operation. No arteriovenous fistula, deep vein thrombosis nor pseudoaneurysm occurred. Conclusion Endovascular treatment for type TASC-D aortoiliac occlusion disease is a safe and effective treatment with less trauma, high patency rate, less complications and immediate effect.

关 键 词：主髂动脉闭塞症 腔内治疗 

分 类 号：R654.4[医药卫生—外科学]